Official websites use .gov
Secure .gov websites use HTTPS
Titles
- FH Healthcare Indicators (TM) and FH Medical Price Index (TM): a new view of place of service trends and medical pricing1
- FH Healthcare Indicators and FH Medical Price Index 2021: an annual view of place of service trends and medical pricing1
- FH Healthcare Indicators and FH Medical Price Index: 2020 : an annual view of place of service trends and medical pricing1
- FH Healthcare Indicators and FH Medical Price Index: 2022 : an annual view of place of service trends and medical pricing1
- FY 2018 medical device user fee small business qualification and certification: guidance for industry, Food and Drug Administration staff and foreign governments1
- Faces of the Medicaid expansion: how obtaining Medicaid coverage impacts low-income adults1
- Facet screw systems: performance criteria for safety and performance based pathway : guidance for industry and Food and Drug Administration staff1
- Facilitating consumer choice: standardized plans in health insurance marketplaces1
- Facilitating implementation of evidence-based guidelines in hospital settings: learning from trauma centers1
- Facility definition under Section 503B of the Federal Food, Drug, and Cosmetic Act1
- Facility fees and how they affect health care prices1
- Facility quality and safety4
- Facility-initiated discharges in nursing homes require further attention1
- Facing the flu: from the bird flu to a possible pandemic : why isn't America ready?1
- Fact sheet. The 340B Drug Pricing Program1
- Factors affecting states' ability to respond to federal Medicaid cuts and caps: which states are most at risk?1
- Factors contributing to reductions in patient wait times at Indian Health Service emergency department facilities: a mixed-methods assessment1
- Factors to consider when making benefit-risk determinations in medical device premarket approval and de novo classifications: guidance for industry and Food and Drug Administration staff1
- Failure to respond to an ANDA complete response letter within the regulatory timeframe1
- Failure to respond to an ANDA complete response letter within the regulatory timeframe: guidance for industry1